Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071965 · ClinicalTrials.gov registry record · Phase 2
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
A Phase 2 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT03071965 is a Phase 2 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT03071965, a Phase 2 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent sham surgery in the respective precursor study (NTMT-01 or NTMT-02). A substudy was conducted in which subjects enrolled in study (NTMT-02), who had 1 study-eligible eye that underwent sham surgery, were offered the option to have NT-501 implanted in the same study eye. Of the 19 subjects who had 1 study-eligible eye and underwent sham surgery in the Cohort 2 precursor study (NTMT-02), 16 subjects elected to have NT-501 implanted in the same study eye during the substudy
Interventions
- PROCEDURE Surgery
- BIOLOGICAL Ciliary neurotrophic factor (CNTF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03071965
The ClinicalTrials.gov registry entry for NCT03071965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT03071965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03071965 about?
NCT03071965 is a clinical study titled "Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)". This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent sham surgery in the respective precursor study (NTMT-01 or NTMT-02). ...
What is the current status of trial NCT03071965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2017-05-12. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT03071965?
The interventions under investigation include: Surgery (PROCEDURE), Ciliary neurotrophic factor (CNTF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03071965?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.